Flurbiprofen

CLINICAL USE

NSAID and analgesic

DOSE IN NORMAL RENAL FUNCTION

150–200 mg daily in divided doses, increased in acute conditions to 300 mg dailyDysmenorrhoea: 50–100 mg every 4–6 hours; maximum 300 mg daily

PHARMACOKINETICS

  • Molecular weight                           :244.3
  • %Protein binding                           :99
  • %Excreted unchanged in urine     : <3
  • Volume of distribution (L/kg)       :0.1–0.2
  • half-life – normal/ESRD (hrs)      :3–6/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function, but avoid if possible
  • 10 to 20     : Dose as in normal renal function, but avoid if possible
  • <10           : Dose as in normal renal function, but only if on dialysis

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Removal very unlikely. Dose as in GFR <10 mL/min.
  • HD                     :Removal very unlikely. Dose as in GFR <10 mL/min.
  • HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min.
  • CAV/VVHD      :Removal very unlikely. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia

  • Analgesics: avoid concomitant use with other NSAIDs or aspirin; avoid concomitant use with ketorolac (increased side effects and haemorrhage)
  • Antibacterials: possibly increased risk of convulsions with quinolones
  • Anticoagulants: effects of coumarins enhanced; possibly increased risk of bleeding with heparins and coumarins
  • Antidepressants: increased risk of bleeding with SSRIs or venlafaxineAntidiabetic agents: effects of sulphonylureas enhanced
  • Anti-epileptics: possibly enhanced effect of phenytoin
  • Antivirals: concentration possibly increased by ritonavir; increased risk of haematological toxicity with zidovudine
  • Ciclosporin: may potentiate nephrotoxicity Cytotoxic agents: reduced excretion of methotrexate; increased risk of bleeding with erlotinib
  • Lithium: excretion reduced (risk of lithium toxicity)
  • Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diureticsPentoxifylline: increased risk of bleeding
  • Tacrolimus: increased risk of nephrotoxicity

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    NSAIDs have been reported to cause nephrotoxicity in various forms; interstitial nephritis, nephrotic syndrome and renal failure. In patients with renal, cardiac or hepatic impairment, caution is required since the use of NSAIDs may result in deterioration of renal functionInhibition of renal prostaglandin synthesis by NSAIDs may interfere with renal function, especially in the presence of existing renal disease – avoid if possible; if not, check serum creatinine 48–72 hours after starting NSAID – if creatinine has increased, discontinue therapyUse normal doses in patients with ERF on dialysis if they do not pass any urineUse with caution in renal transplant recipients – can reduce intrarenal autocoid synthesis.

  • Related News